Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 6/2010

01-11-2010

Treatment of Resistant Enterococcal Urinary Tract Infections

Authors: Subramanian Swaminathan, George J. Alangaden

Published in: Current Infectious Disease Reports | Issue 6/2010

Login to get access

Abstract

Enterococcus spp have emerged as important pathogens in urinary tract infection (UTI), especially in hospitalized patients. Resistance to multiple antibiotics, including vancomycin, has become common, particularly in infections involving Enterococcus faecium. The management of UTIs caused by Enterococcus spp has become challenging given the presence of underlying comorbidities in these patients and the limited therapeutic options available to treat multidrug-resistant (MDR) Enterococcus. Routine therapy for asymptomatic bacteriuria with MDR-Enterococcus is not recommended. Removal of indwelling urinary catheters should be considered. Appropriate antibiotic therapy selection should be guided by urine culture and susceptibility results. Data are limited on the treatment of UTIs caused by MDR-Enterococcus. Potential oral agents active against MDR-Enterococcus that may be considered for acute uncomplicated UTI include nitrofurantoin, fosfomycin, and fluoroquinolones. Potential parenteral agents for the treatment of pyelonephritis and complicated UTIs caused by MDR-Enterococcus include daptomycin, linezolid, and quinipristin-dalfopristin. Aminoglycosides or rifampin may be considered as adjunctive therapy in serious infections.
Literature
1.
• Hidron AI, Edwards JR, Patel J, et al.: Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008, 29:996–1011. This article provides a good overview of the magnitude of health-care associated infections caused by VRE.CrossRefPubMed
2.
Fisher K, Phillips C: The ecology, epidemiology and virulence of Enterococcus. Microbiology 2009, 155:1749–1757.CrossRefPubMed
3.
Willems RJ, Bonten MJ: Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007, 20:384–390. CrossRefPubMed
4.
Martone WJ: Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998, 19:539–545.CrossRefPubMed
5.
Bonten MJ, Willems R, Weinstein RA: Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001, 1:314–325.CrossRefPubMed
6.
7.
Murray BE: The life and times of the enterococcus. Clin Microbiol Rev. 1990, 3:46–65.PubMed
8.
Hodges TL, Zighelboim-Daum S, Eliopoulos GM, et al.: Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens. Antimicrob Agents Chemother 1992, 36:121–125.PubMed
9.
Murray BE: Vancomycin resistant enterococcal infections. New Engl J Med 2000, 324:710–712.
10.
Ono S, Muratani T, Matsumoto T: Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother 2005, 49:2954–2958.CrossRefPubMed
11.
Rybkine T, Mainardi JL, Sougakoff W, et al. : Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis 1998, 178:159–163.PubMed
12.
Chang S, Sievert DM, Hageman JC, et al.; Vancomycin-Resistant Staphylococcus aureus Investigative Team: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342–1347.CrossRefPubMed
13.
Warren DK, Nitin A, Hill C, et al.: Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004, 25:99–104.CrossRefPubMed
14.
Zhanel GG, Laing NM, Nichol KA, et al.: Antibiotic activity against UTI isolates of VRE: results from the 2002 NAVRESS. J Antimicrob Chemother 2003, 53:382–388.CrossRef
15.
Bonten MJ, Slaughter S, Ambergen AW, et al.: The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998, 158:1127–1132.CrossRefPubMed
16.
Młynarczyk G, Grzybowska W, Młynarczyk A, et al.: Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004–2005. Transplant Proc 2007, 39:2883–2885.CrossRefPubMed
17.
Chavers LS, Moser SA, Benjamin WH, et al.: Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect 2003, 53:159–171.CrossRefPubMed
18.
Lucas GM, Lechtzin N, Puryear DW, et al.: Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998, 26:1127–1133.CrossRefPubMed
19.
Patel R, Allen SL, Manahan JM, et al.: Natural history of vancomycin resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transplantation 2001, 7:27–31.CrossRefPubMed
20.
Singh KV, Nallapareddy SR, Murray BE: Importance of the ebp (endocarditis and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 2007, 195:1671–1677.CrossRefPubMed
21.
Kapur D, Dorsky D, Feingold JM, et al.: Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2000, 25:147–152.CrossRefPubMed
22.
Se Y-B, Chun H-J, Yi H-J, et al.: Incidence and risk factors of infection caused by vancomycin-resistant enterococcus colonization in neurosurgical intensive care unit patients. J Korean Neurosurg Soc 2009, 46:123–129.CrossRefPubMed
23.
Patel R, Allen SL, Manahan JM, et al.: Natural history of vancomycinresistant enterococcal colonization in liver and kidney transplant recipients. Liver Transplant 2001, 7:27–31.CrossRef
24.
Horan TC, White JW, Jarvis WR, et al.: Nosocomial infection surveillance, 1984. MMWR Morb Mortal Wkly Rep 1986, 35(1SS):17SS–29SS.
25.
Fleenor-Ford A, Hayden MK, Weinstein RA: Vancomycin-resistant enterococci: implications for surgeons. Surgery 1999, 125:121–125.CrossRefPubMed
26.
•• Hooten TM, Bradley SF, Cardenas DD, et al.: Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:625–663. This article describes current IDSA guidelines on catheter-associated urine infections, including differentiation from colonization.
27.
Shay DK, Maloney SA, Montecalvo M, et al.: Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995, 172:993–1000.PubMed
28.
Alangaden GJ, Thyagarajan R, Gruber SA, et al.: Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006, 20:401–409.CrossRefPubMed
29.
Wong AHM, Wenzel RP, Edmond MB: Epidemiology of bacteriuria caused by vancomycin-resistant enterococci—a retrospective study. Am J Infect Control 2000, 28:277–281.CrossRefPubMed
30.
Edmond MB, Ober JF, Weinbaum DL, et al.: Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995, 20:1126–1133.PubMed
31.
32.
Mainardi JL, Gutmann L, Acar JF, Goldstein FW: Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 1995, 39:1984–1987.PubMed
33.
• Gavalda J, Len O, Miro JM, et al.: Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007, 8:574–579. Treatment of enterococcal endocarditis with ampicillin and ceftriaxone was shown to be effective, making this an option for aminoglycoside-resistant strains.
34.
Brandt CM, Rouse MS, Laue NW, et al.: Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 1996, 173:909–913.PubMed
35.
Warren JW, Abrutyn E, Hebel JR, et al.: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999, 29:745–758.CrossRefPubMed
36.
37.
Patel SS, Balfour JA, Bryson HM: Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53:637–656.CrossRefPubMed
38.
Falagas ME, Vouloumanou SK, Togias AG, et al.: Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862–1877.CrossRefPubMed
39.
Fuchs PC, Barry AL, Brown SD: Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999, 43:137–140.CrossRefPubMed
40.
Bonadio M, Meini M, Tagliaferri E, et al.: Enterococcal glycopeptide resistance at an Italian teaching hospital. J Antimicrob Chemother 2000, 46:129–131.CrossRefPubMed
41.
Perri MB, Hershberger E, Ionescu M, et al.: In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002, 42:269–271.CrossRefPubMed
42.
Shrestha NK, Chua JD, Tuohy MJ, et al.: Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003, 35:12–14.CrossRefPubMed
43.
Cilli F, Pullukcu H, Aydemir S, et al.: In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates. Int J Antimicrob Agents 2008, 31:297–298.CrossRefPubMed
44.
Maraki S, Samonis G, Rafailidis PI, et al.: Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009, 53:4508–4510.CrossRefPubMed
45.
Shrestha NK, Amuh D, Goldman MP, et al.: Treatment of a complicated vancomycin-resistant enterococcal urinary tract infection with fosfomycin. Infect Dis Clin Pract 2000, 9:368–371.CrossRef
46.
Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069–1077.CrossRefPubMed
47.
Naber KG, Allin DM, Clarysse L, et al.: Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004, 23:596–605.CrossRefPubMed
48.
Naber KG, Bartnicki A, Bischoff W, et al.: Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004, 23(Suppl 1):S41–S53.CrossRefPubMed
49.
Linden PK: Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002, 62:425–441.CrossRefPubMed
50.
Norris AH, Reilly JP, Edelstein PH, et al.: Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995, 20:1137–1144.PubMed
51.
Lautenbach E, Schuster MG, Biler WB, et al.: The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998, 27:1259–1265.CrossRefPubMed
52.
Linden PK, Moellering RC Jr, Wood CA, et al.: Treatment of vancomycin-resistant Enterococcus faecium infections with quinipristin/dalfopristin. Clin Infect Dis 2001, 33:1816–1823.CrossRefPubMed
53.
•• Arias CA, Contreras GA, Murray BE: Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 2010, 16:555–562. This article provides a detailed review of treatment options for VRE.CrossRefPubMed
54.
Shea K, Hilburger E, Baroco A, Oldfield E: Successful treatment of vancomycin-resistant enterococcus faecium pyelonephritis with daptomycin during pregnancy. Ann Pharmacother 2008, 42:722–725.CrossRefPubMed
55.
Wagenlehner FM, Wydra S, Onda H, et al.: Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003, 47:3789–3794.CrossRefPubMed
56.
Birmingham MC, Rayner CR, Meagher AK, et al.: Linezolid for the treatment of multidrug-resistant, gram positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 2:159–168.CrossRef
57.
Pogue JM, Paterson DL, Pasculle AW, Potoski BA: Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2007, 28:1382–1388.CrossRefPubMed
58.
Eisenstein BI: Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin Investig Drugs 2004, 13:1159–1169.CrossRefPubMed
59.
Wagenlehner FM, Naber KG: New drugs for gram-positive uropathogens. Int J Antimicrob Agents 2004, 24(Suppl 1):S39–S43.CrossRefPubMed
60.
Sapico FL, Ginunas VJ, Canawati HN, Montgomerie JZ: LY146032, alone and in combination with gentamicin, for the treatment of enterococcal pyelonephritis in the rat model. Antimicrob Agents Chemother 1988, 32:81–83.PubMed
61.
Arias CA, Torres HA, Singh KV, et al.: Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007, 10:1343–1346.CrossRef
62.
Stevens MP, Edmond MB: Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005, 8:1134–1142.CrossRef
63.
Naber KG, Eisenstein BI, Tally FP: Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. Infect Dis Clin Pract 2004, 12:322–327.CrossRef
64.
Fisher L, North D: Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agent 2009, 33:493–494.CrossRef
65.
66.
Hoban DJ, Bouchillon SK, Johnson BM, et al.; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group: In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005, 52:215–227.CrossRefPubMed
67.
Ellis-Grosse EJ, Babinchak T, Dartois N, et al.; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341–S53.CrossRefPubMed
68.
Babinchak T, Ellis-Grosse E, Dartois N, et al.; Tigecycline 301 Study Group; Tigecycline 306 Study Group: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354–S67.CrossRefPubMed
69.
Nix DE, Matthias KR: Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010, 65:1311–1312.CrossRefPubMed
70.
71.
Lefort A, Saleh-Mghir A, Garry L, et al.: Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 2000, 44:3017–3021.CrossRefPubMed
Metadata
Title
Treatment of Resistant Enterococcal Urinary Tract Infections
Authors
Subramanian Swaminathan
George J. Alangaden
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 6/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-010-0138-8

Other articles of this Issue 6/2010

Current Infectious Disease Reports 6/2010 Go to the issue

ReviewPaper

In Vitro Susceptibility Testing in Fungi: What is its Role in Clinical Practice?

ReviewPaper

The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses

ReviewPaper

Clinical Spectrum of Desquamative Inflammatory Vaginitis

ReviewPaper

Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights

ReviewPaper

Spinal Epidural Abscess: Current Diagnosis and Management

ReviewPaper

Advances and Prospects for Molecular Diagnostics of Fungal Infections
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits